← Back to Search

Checkpoint Inhibitor

Y90 radioembolization for Liver Cancer

Q: What medical applications does Y90 radioembolization typically serve?

Y90 radioembolization is widely used to treat malignant tumours, but it can also be a viable solution for unresectable <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a>, microsatellite instability high positions, and chemotherapy-resistant conditions.

Q: Has research involving Y90 radioembolization been conducted previously?

The amount of current clinical trials exploring Y90 radioembolization is 962, with 122 being in Phase 3. These various studies are predominantly based in Houston, <a href="https://www.withpower.com/clinical-trials/texas">Texas</a> but span a total of 35,769 different locations.

Q: What is the current capacity for this experiment?

This research project is no longer actively enrolling candidates. Initially posted on March 28th 2017, the trial was most recently updated on August 31st 2022 and is now closed to incoming participants. However, there are presently 2609 trials recruiting patients with carcinoma hepatocellular and 962 studies seeking individuals for Y90 radioembolization treatment.

Q: Are any slots available for volunteers in the current experiment?

This clinical trial has concluded recruitment, having been first posted on March 28th 2017 and last updated August 31st 2022. Nevertheless, patients could always search for other studies; presently there are 2609 trials looking to enroll individuals with carcinoma hepatocellular and 962 searching for candidates for Y90 radioembolization.

Phase < 1

Waitlist Available

Led By Ashwin Somasundaram, MD

Research Sponsored by Autumn McRee, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is designed to see if combining pembrolizumab with Yttrium-90 radioembolization is an effective treatment for subjects with poor prognosis HCC who are not eligible for liver transplant or surgical resection.

Eligible Conditions

Liver Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression free survival (PFS)

Secondary outcome measures

Assess Safety - toxicities as defined by the NCI CTCAE v4

Estimate overall survival (OS)

Objective response rate (ORR)

+1 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

1Treatment groups

Experimental Treatment

Group I: pembrolizumab + Y90 radioembolizationExperimental Treatment2 Interventions

Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Autumn McRee, MDLead Sponsor

1 Previous Clinical Trials

18 Total Patients Enrolled

Ashwin SomasundaramLead Sponsor

1 Previous Clinical Trials

18 Total Patients Enrolled

Merck Sharp & Dohme LLCIndustry Sponsor

3,892 Previous Clinical Trials

5,061,116 Total Patients Enrolled

2 Trials studying Liver Cancer

133 Patients Enrolled for Liver Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What medical applications does Y90 radioembolization typically serve?

"Y90 radioembolization is widely used to treat malignant tumours, but it can also be a viable solution for unresectable melanoma, microsatellite instability high positions, and chemotherapy-resistant conditions."

Answered by AI

Has research involving Y90 radioembolization been conducted previously?

"The amount of current clinical trials exploring Y90 radioembolization is 962, with 122 being in Phase 3. These various studies are predominantly based in Houston, Texas but span a total of 35,769 different locations."

Answered by AI

What is the current capacity for this experiment?

"This research project is no longer actively enrolling candidates. Initially posted on March 28th 2017, the trial was most recently updated on August 31st 2022 and is now closed to incoming participants. However, there are presently 2609 trials recruiting patients with carcinoma hepatocellular and 962 studies seeking individuals for Y90 radioembolization treatment."

Answered by AI

Are any slots available for volunteers in the current experiment?

"This clinical trial has concluded recruitment, having been first posted on March 28th 2017 and last updated August 31st 2022. Nevertheless, patients could always search for other studies; presently there are 2609 trials looking to enroll individuals with carcinoma hepatocellular and 962 searching for candidates for Y90 radioembolization."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Ashwin Somasundaram 2017. "Pembrolizumab Plus Y90 Radioembolization in HCC Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03099564.